Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,830 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT06869447Recruiting
Better Breathing After Lung Cancer Treatment
This study looks at breathing exercises for people who have finished treatment for early-stage lung cancer. You'll be asked to give a blood sample at home and do breathing training to see if it helps your recovery.
Buffalo, New YorkAges 18 years+ - NCT07285434Enrolling by invitationEarly Phase 1
Personalized vaccine for first-line advanced lung cancer
This study tests a personalized vaccine (Microlyvaq™) made just for your tumor, given together with standard chemo and immunotherapy (pembrolizumab). It is for people with advanced non-small cell lung cancer who have not yet started treatment for the advanced stage.
Thessaloniki, MacedoniaAges Any age - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05544240RecruitingPhase 1
First-in-human immunotherapy study for advanced solid tumors
This Phase 1 trial tests SYNC-T, an immunotherapy, in people with advanced or metastatic solid cancers. It aims to find the safest dose and see whether the treatment can shrink or control tumors.
Mexico CityAges 18 years+ - NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
Phoenix, ArizonaAges 18 years+ - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT07608848RecruitingEarly Phase 1
Imaging study of new cancer-targeting radioactive drugs
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Perth, Western AustraliaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
Gainesville, FloridaAges 18 years+ - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT06278454RecruitingPhase 1
Radioactive injection for advanced pancreatic cancer
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
Zhengzhou, HenanAges 18–80 - NCT06917573RecruitingPhase 2
Cemiplimab for advanced lung cancer with high PD-L1
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Alicante, AlicanteAges 18 years+ - NCT07505173RecruitingPhase 2
Targeted radiation plus osimertinib for brain metastases from EGFR-mutant lung cancer
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
TianjinAges 18–75 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07603856RecruitingPhase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
Chicago, IllinoisAges 18 years+ - NCT07227298RecruitingPhase 1/Phase 2
Study of new drug combo for advanced lung cancer
This study tests a new combination of cancer drugs (PF-08634404 with other anticancer agents) for people with advanced non-small cell lung cancer who have not yet received any treatment for their advanced disease. It aims to see if this combination can shrink tumors or slow cancer growth.
Fayetteville, ArkansasAges 18 years+ - NCT07472517RecruitingPhase 3
Comparing a new drug combo for advanced small cell lung cancer
This trial tests a new investigational drug called obrixtamig combined with standard chemotherapy (atezolizumab, carboplatin, etoposide) for people with advanced small cell lung cancer that has spread. It aims to see if this new combination works better than the standard treatment alone.
Mobile, AlabamaAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,830 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.